Goebelsmann, U. 1986. Pharmacokinetics of contraceptive steroids in humans. Pp. 67-111 in Contraceptive Steroids: Pharmacology and Safety, A. T. Gregoire and R. T. Blye, eds. New York: Plenum Press.

Goldzieher, J. W. 1990. Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical application. American Journal of Obstetrics and Gynecology 163: 318-322

Jung-Hoffmann, C., F. Heidt, and H. Kuhl. 1988. Effect of two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel upon various hormonal parameters. Contraception 38: 593-603

Kloosterboer, H. J., C. A. Vonk-Noordegraaf, and E. W. Turpijn. 1988. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception 38: 325-332

Kuhl, H., C. Jung-Hoffmann, and F. Heidt. 1988a. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel. Contraception 38: 381-390

Kuhl, H., C. Jung-Hoffmann, and F. Heidt. 1988b. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 75 μg gestodene. Contraception 38: 477-486

Pike, M. C., R. K. Ross, R. A. Lobo, T. J. A. Key, M. Potts, and B. E. Henderson. 1989. LHRH agonists and the prevention of breast and ovarian cancer. British Journal of Cancer 60: 142-148

Simard, J., S. Dauvois, D. E. Haagensen, C. Levesque, Y. Merand, and F. Labrie. 1990. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: A new marker of steroid action in breast cancer. Endocrinology 126: 3223-3231